Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2170588 | 1.00 | CNR2 (0.44) | CNR2 | |
| SCHEMBL944178 | 0.99 | CNR2 (0.44) | CNR2 | |
| SCHEMBL3386311 | 0.99 | CNR2 (0.44) | CNR2 | |
| SCHEMBL944177 | 0.99 | CNR2 (0.44) | CNR2 | |
| SCHEMBL3217404 | 0.86 | CNR2 (0.37) | CNR2 | |
| SCHEMBL3217392 | 0.86 | CNR2 (0.37) | CNR2 | |
| SCHEMBL943969 | 0.83 | KDM4E (0.44) | CNR2 | |
| SCHEMBL944233 | 0.81 | KMT2A (0.41) | CNR2 | |
| SCHEMBL3386784 | 0.81 | ALDH1A1 (0.41) | CNR2 | |
| SCHEMBL944234 | 0.81 | KMT2A (0.41) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546242-B1 | Cannabinoid receptor ligands | ABBVIE INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2457903-B1 | Cannabinoid receptor ligands | ABBVIE INC (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2546241-B1 | Cannabinoid receptor ligands | ABBVIE INC (US) | 2015-06-17 | — | — | EP | disclosed |
| US-8846730-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2546241-A1 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2457903-A1 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2346843-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100063022-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2010028338-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | CNR2 2/4885 |
| US-20100063022-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.